Antony, France; 7 May 2014 - The Global Asthma and Allergy European Network (GA²LEN), together with three leading allergen immunotherapy companies, Stallergenes, Allergopharma and LETI, have announced the signature of a non-binding letter of intent to jointly develop mobile environmental exposure chambers. Upon receipt of approval from applicable authorities, they will create a jointly owned company which will be in charge of the development, use and commercialization of the chambers.

Through these mobile environmental exposure chambers, companies developing allergen immunotherapy and symptomatic therapeutic products will be able to conduct innovative clinical studies for current and new compounds. These mobile chambers may be used in the field of allergen immunotherapy but also for clinical studies on allergy symptomatic drugs, asthma, or other environmental substances.

ABOUT ENVIRONMENTAL EXPOSURE CHAMBERS

The Environmental Exposure Chamber is a specially designed facility that enables study participants to be exposed to relevant allergens in a controlled, indoor setting. The chambers enable clinical studies in an environment that mimics the natural environment, while at the same time reducing the variability of nature. 

Initially, environmental exposure chambers were used to investigate occupational exposures but were subsequently adapted to investigate treatment of seasonal allergic rhinitis (SAR) and, more recently, perennial allergic rhinitis with antihistamines, nasal corticosteroids, nasal antihistamines, and allergen immunotherapy. Most of the current systems are stationary chambers, which are used primarily for phase I and II studies. 

distributed by